{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:44Z","timestamp":1791874724192,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00467-017-3849-3","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T06:10:08Z","timestamp":1521699008000},"page":"365-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics"],"prefix":"10.1007","volume":"34","author":[{"given":"Dalvir","family":"Kular","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9098-8611","authenticated-orcid":false,"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"3849_CR1","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00467-010-1538-6","volume":"25","author":"MA Atkinson","year":"2010","unstructured":"Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25:1699\u20131706","journal-title":"Pediatr Nephrol"},{"key":"3849_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2215\/CJN.05301107","volume":"4","author":"AO Staples","year":"2009","unstructured":"Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA (2009) Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4:48\u201356","journal-title":"Clin J Am Soc Nephrol"},{"key":"3849_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00467-003-1214-1","volume":"18","author":"BA Warady","year":"2003","unstructured":"Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055\u20131062","journal-title":"Pediatr Nephrol"},{"key":"3849_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.ajkd.2004.08.024","volume":"44","author":"A Gerson","year":"2004","unstructured":"Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017\u20131023","journal-title":"Am J Kidney Dis"},{"key":"3849_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/DBP.0000000000000267","volume":"37","author":"SR Hooper","year":"2016","unstructured":"Hooper SR, Gerson AC, Johnson RJ, Mendley SR, Shinnar S, Lande MB, Matheson MB, Gipson DS, Morgenstern B, Warady BA, Furth SL (2016) Neurocognitive, social-behavioral, and adaptive functioning in preschool children with mild to moderate kidney disease. J Dev Behav Pediatr 37:231\u2013238","journal-title":"J Dev Behav Pediatr"},{"key":"3849_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2006.08.017","volume":"149","author":"MM Mitsnefes","year":"2006","unstructured":"Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671\u2013675","journal-title":"J Pediatr"},{"key":"3849_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1681\/ASN.2005030276","volume":"17","author":"MC Matteucci","year":"2006","unstructured":"Matteucci MC, Wuhl E, Picca S, Mastrostefano A, Rinelli G, Romano C, Rizzoni G, Mehls O, de Simone G, Schaefer F (2006) Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 17:218\u2013226","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR8","first-page":"1361","volume":"58","author":"JC Scornik","year":"1994","unstructured":"Scornik JC, Pfaff WW, Howard RJ, Fennell RS 3rd, Ramos E, Peterson JC, Neiberger R (1994) Increased antibody responsiveness to blood transfusions in pediatric patients. Transplantation 58:1361\u20131365","journal-title":"Transplantation"},{"key":"3849_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1471-2369-14-217","volume":"14","author":"JC Scornik","year":"2013","unstructured":"Scornik JC, Bromberg JS, Norman DJ, Bhanderi M, Gitlin M, Petersen J (2013) An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol 14:217","journal-title":"BMC Nephrol"},{"key":"3849_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1681\/ASN.2012050433","volume":"24","author":"D Borzych-Duzalka","year":"2013","unstructured":"Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665\u2013676","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00467-008-0954-3","volume":"24","author":"OF Bamgbola","year":"2009","unstructured":"Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24:571\u2013579","journal-title":"Pediatr Nephrol"},{"key":"3849_CR12","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP (2009) Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53:823\u2013834","DOI":"10.1053\/j.ajkd.2008.12.040"},{"key":"3849_CR13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00467-014-2820-9","volume":"29","author":"RM Lestz","year":"2014","unstructured":"Lestz RM, Fivush BA, Atkinson MA (2014) Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 29:2021\u20132028","journal-title":"Pediatr Nephrol"},{"key":"3849_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","volume":"61","author":"I Koulouridis","year":"2013","unstructured":"Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44\u201356","journal-title":"Am J Kidney Dis"},{"key":"3849_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000337820","volume":"178","author":"MV Prabhu","year":"2012","unstructured":"Prabhu MV, Nayak A, Sridhar G, Subhramanyam SV, Nayak KS (2012) Maximizing the erythropoietin response: iron strategies. Contrib Nephrol 178:95\u201399","journal-title":"Contrib Nephrol"},{"key":"3849_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2006091034","volume":"18","author":"DW Coyne","year":"2007","unstructured":"Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis Patients' response to IV iron with elevated Ferritin (DRIVE) study. J Am Soc Nephrol 18:975\u2013984","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1681\/ASN.2007050606","volume":"19","author":"T Kapoian","year":"2008","unstructured":"Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW (2008) Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19:372\u2013379","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/14712598.2012.672968","volume":"12","author":"W Jelkmann","year":"2012","unstructured":"Jelkmann W (2012) Biosimilar recombinant human erythropoietins (\"epoetins\") and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther 12:581\u2013592","journal-title":"Expert Opin Biol Ther"},{"key":"3849_CR19","first-page":"1","volume":"11","author":"JG Hollowell","year":"2005","unstructured":"Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C (2005) Hematological and iron-related analytes--reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11:1\u2013156","journal-title":"Vital Health Stat"},{"key":"3849_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO (2012) Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:1\u2013335","journal-title":"Kidney Int Suppl"},{"key":"3849_CR21","unstructured":"NICE guideline (2015) Chronic kidney disease: managing anaemia. NG8. Available from www.nice.org.uk"},{"key":"3849_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.kint.2016.10.006","volume":"91","author":"M Hattori","year":"2017","unstructured":"Hattori M (2017) Hemoglobin target in children with chronic kidney disease: valuable new information. Kidney Int 91:16\u201318","journal-title":"Kidney Int"},{"key":"3849_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.kint.2016.09.013","volume":"91","author":"MN Rheault","year":"2017","unstructured":"Rheault MN, Molony JT, Nevins T, Herzog CA, Chavers BM (2017) Hemoglobin of 12 g\/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. Kidney Int 91:177\u2013182","journal-title":"Kidney Int"},{"key":"3849_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14740338.2016.1218467","volume":"15","author":"T Hermanson","year":"2016","unstructured":"Hermanson T, Bennett CL, Macdougall IC (2016) Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf 15:1421\u20131426","journal-title":"Expert Opin Drug Saf"},{"key":"3849_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589:1251\u20131258","journal-title":"J Physiol"},{"key":"3849_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1681\/ASN.2013010030","volume":"24","author":"T Souma","year":"2013","unstructured":"Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, Abe M, Kiyomoto H, Ito S, Yamamoto M (2013) Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 24:1599\u20131616","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR27","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2015050508","volume":"27","author":"S Seigneux de","year":"2016","unstructured":"de Seigneux S, Lundby AK, Berchtold L, Berg AH, Saudan P, Lundby C (2016) Increased synthesis of liver erythropoietin with CKD. J Am Soc Nephrol 27:2265\u20132269","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000098522","volume":"30","author":"J Malyszko","year":"2007","unstructured":"Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30:15\u201330","journal-title":"Kidney Blood Press Res"},{"key":"3849_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr, Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30:393\u2013402","journal-title":"Mol Cell"},{"key":"3849_CR30","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1681\/ASN.2010010116","volume":"21","author":"WM Bernhardt","year":"2010","unstructured":"Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21:2151\u20132156","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/cdd.2008.12","volume":"15","author":"A Weidemann","year":"2008","unstructured":"Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15:621\u2013627","journal-title":"Cell Death Differ"},{"key":"3849_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00424-015-1740-2","volume":"468","author":"N Suzuki","year":"2016","unstructured":"Suzuki N, Yamamoto M (2016) Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch 468:3\u201312","journal-title":"Pflugers Arch"},{"key":"3849_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V74.2.645.bloodjournal742645","volume":"74","author":"ST Koury","year":"1989","unstructured":"Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE (1989) Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74:645\u2013651","journal-title":"Blood"},{"key":"3849_CR34","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1182\/blood-2007-10-115857","volume":"111","author":"N Obara","year":"2008","unstructured":"Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M (2008) Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111:5223\u20135232","journal-title":"Blood"},{"key":"3849_CR35","doi-asserted-by":"publisher","first-page":"19533","DOI":"10.1074\/jbc.M111.238667","volume":"286","author":"ER Anderson","year":"2011","unstructured":"Anderson ER, Xue X, Shah YM (2011) Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis. J Biol Chem 286:19533\u201319540","journal-title":"J Biol Chem"},{"key":"3849_CR36","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","volume":"140","author":"M Taylor","year":"2011","unstructured":"Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ, Shah YM (2011) Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 140:2044\u20132055","journal-title":"Gastroenterology"},{"key":"3849_CR37","doi-asserted-by":"publisher","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","volume":"272","author":"A Rolfs","year":"1997","unstructured":"Rolfs A, Kvietikova I, Gassmann M, Wenger RH (1997) Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272:20055\u201320062","journal-title":"J Biol Chem"},{"key":"3849_CR38","doi-asserted-by":"publisher","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","volume":"274","author":"L Tacchini","year":"1999","unstructured":"Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274:24142\u201324146","journal-title":"J Biol Chem"},{"key":"3849_CR39","doi-asserted-by":"publisher","first-page":"21048","DOI":"10.1074\/jbc.M000636200","volume":"275","author":"CK Mukhopadhyay","year":"2000","unstructured":"Mukhopadhyay CK, Mazumder B, Fox PL (2000) Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275:21048\u201321054","journal-title":"J Biol Chem"},{"key":"3849_CR40","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1172\/JCI63924","volume":"122","author":"Q Liu","year":"2012","unstructured":"Liu Q, Davidoff O, Niss K, Haase VH (2012) Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 122:4635\u20134644","journal-title":"J Clin Invest"},{"key":"3849_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46:678\u2013684","journal-title":"Nat Genet"},{"key":"3849_CR42","unstructured":"(2007) Adverse event of FG-2216 for the treatment of anemia. Available at: https:\/\/www.astellas.com\/en\/corporate\/news\/pdf\/070507_eg.pdf . Accessed 30 June 2017"},{"key":"3849_CR43","doi-asserted-by":"publisher","first-page":"9369","DOI":"10.1021\/jm400386j","volume":"56","author":"MH Rabinowitz","year":"2013","unstructured":"Rabinowitz MH (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem 56:9369\u20139402","journal-title":"J Med Chem"},{"key":"3849_CR44","unstructured":"Astellas (2008) The FDA accepts the complete response for clinical holds of FG-2216*\/FG-4592 for the treatment of anemia. Available at https:\/\/www.astellas.com\/en\/corporate\/news\/pdf\/080402_eg.pdf . Accessed 1 July 2017"},{"key":"3849_CR45","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","volume":"30","author":"A Besarab","year":"2015","unstructured":"Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB (2015) Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 30:1665\u20131673","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR46","doi-asserted-by":"publisher","first-page":"M880","DOI":"10.1097\/00002480-199407000-00122","volume":"40","author":"RP Ross","year":"1994","unstructured":"Ross RP, McCrea JB, Besarab A (1994) Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J 40:M880\u2013M885","journal-title":"ASAIO J"},{"key":"3849_CR47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1152\/jappl.1985.59.2.360","volume":"59","author":"JS Milledge","year":"1985","unstructured":"Milledge JS, Cotes PM (1985) Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol 59:360\u2013364","journal-title":"J Appl Physiol"},{"key":"3849_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2215\/CJN.06890615","volume":"11","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB (2016) Oral hypoxia-inducible factor Prolyl Hydroxylase inhibitor Roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 11:982\u2013991","journal-title":"Clin J Am Soc Nephrol"},{"key":"3849_CR49","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1681\/ASN.2015030241","volume":"27","author":"A Besarab","year":"2016","unstructured":"Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB (2016) Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27:1225\u20131233","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","volume":"67","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB (2016) Roxadustat (FG-4592) versus Epoetin Alfa for anemia in patients receiving maintenance Hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67:912\u2013924","journal-title":"Am J Kidney Dis"},{"key":"3849_CR51","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH (2017) Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 32:1373\u20131386","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR52","unstructured":"FibroGen\u2019s Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China. Available at: http:\/\/investor.fibrogen.com\/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2240513 . Accessed 1 July 2017"},{"key":"3849_CR53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12325-017-0508-9","volume":"34","author":"K Becker","year":"2017","unstructured":"Becker K, Saad M (2017) A new approach to the Management of Anemia in CKD patients: a review on Roxadustat. Adv Ther 34:848\u2013853","journal-title":"Adv Ther"},{"key":"3849_CR54","unstructured":"European Medicines Agency (EMA) roxadustat PIP decision. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500183791.pdf . Accessed 31 July 2017"},{"key":"3849_CR55","unstructured":"Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S. Available at: https:\/\/www.otsuka-us.com\/discover\/articles-985 . Accessed 1 July 2017"},{"key":"3849_CR56","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM (2017) Clinical trial of Vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol 45:380\u2013388","journal-title":"Am J Nephrol"},{"key":"3849_CR57","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH (2016) Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90:1115\u20131122","journal-title":"Kidney Int"},{"key":"3849_CR58","unstructured":"European Medicines Agency (EMA) vadadustat PIP decision. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500223972.pdf . Accessed 31 July 2017"},{"key":"3849_CR59","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR (2016) Four-week studies of oral hypoxia-inducible factor-Prolyl Hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27:1234\u20131244","journal-title":"J Am Soc Nephrol"},{"key":"3849_CR60","unstructured":"GSK Medicine: GSK1278863. Available at: https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-113633-clinical-study-result-summary.pdf . Accessed 1 July 2017"},{"key":"3849_CR61","unstructured":"GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease. Available at: http:\/\/us.gsk.com\/en-us\/media\/press-releases\/2016\/gsk-starts-phase-iii-programme-with-daprodustat-for-anaemia-associated-with-chronic-kidney-disease\/ . Accessed 1 July 2017"},{"key":"3849_CR62","unstructured":"European Medicines Agency (EMA) Daprodustat PIP \u00b0ion. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500171723.pdf . Accessed 31 July 2017"},{"key":"3849_CR63","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.04","volume":"31","author":"IC Macdougall","year":"2016","unstructured":"Macdougall IC, Akizawa T, Berns J, Lentini S, Bernhardt T (2016) SO036 Molidustat increases hemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND). Nephrol Dial Transplant 31:i16\u2013i16","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR64","first-page":"i193","volume":"31","author":"IC Macdougall","year":"2016","unstructured":"Macdougall IC, Akizawa T, Berns J, Lentini S, Bernhardt T, Kr\u00fcger T (2016) SP309 safety and efficacy of Molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND). Nephrol Dial Transplant 31:i193\u2013i193","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR65","unstructured":"European Medicines Agency (EMA) Molidustat PIP Decision. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500178034.pdf . Accessed 31 July 2017"},{"key":"3849_CR66","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1093\/ndt\/gfl479","volume":"21","author":"CP Schmitt","year":"2006","unstructured":"Schmitt CP, Nau B, Brummer C, Rosenkranz J, Schaefer F (2006) Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. Nephrol Dial Transplant 21:3520\u20133524","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ndt\/gfu297","volume":"30","author":"IC Macdougall","year":"2015","unstructured":"Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, Kribben A, Fliser D, Messner H, McNeil J, Stevens P, Santoro A, De Francisco AL, Percheson P, Potamianou A, Foucher A, Fife D, Merit V, Vercammen E (2015) Incidence of erythropoietin antibody-mediated pure red cell aplasia: the prospective immunogenicity surveillance registry (PRIMS). Nephrol Dial Transplant 30:451\u2013460","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11906-016-0629-6","volume":"18","author":"F Yousaf","year":"2016","unstructured":"Yousaf F, Spinowitz B (2016) Hypoxia-inducible factor stabilizers: a new avenue for reducing BP while helping hemoglobin? Curr Hypertens Rep 18:23","journal-title":"Curr Hypertens Rep"},{"key":"3849_CR69","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2008-04-153718","volume":"112","author":"DP Gale","year":"2008","unstructured":"Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH (2008) Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 112:919\u2013921","journal-title":"Blood"},{"key":"3849_CR70","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/MCB.01055-15","volume":"36","author":"PP Kapitsinou","year":"2016","unstructured":"Kapitsinou PP, Rajendran G, Astleford L, Michael M, Schonfeld MP, Fields T, Shay S, French JL, West J, Haase VH (2016) The endothelial Prolyl-4-Hydroxylase domain 2\/hypoxia-inducible factor 2 Axis regulates pulmonary artery pressure in mice. Mol Cell Biol 36:1584\u20131594","journal-title":"Mol Cell Biol"},{"key":"3849_CR71","first-page":"e180","volume":"34","author":"L Demopoulos","year":"2014","unstructured":"Demopoulos L (2014) Lack of correlation between PK and changes in pulmonary artery systolic pressure in healthy volunteers following administration of the HIF-prolyl hydroxylase inhibitor, GSK1278863. ACCP Annual Meeting Texas 34:e180\u2013e298","journal-title":"ACCP Annual Meeting Texas"},{"key":"3849_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HP.S130526","volume":"5","author":"TW Seeley","year":"2017","unstructured":"Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY (2017) Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia (Auckl) 5:1\u20139","journal-title":"Hypoxia (Auckl)"},{"key":"3849_CR73","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/bonekey.2015.99","volume":"4","author":"E Schipani","year":"2015","unstructured":"Schipani E, Mangiavini L, Merceron C (2015) HIF-1alpha and growth plate development: what we really know. BoneKEy reports 4:730","journal-title":"BoneKEy reports"},{"key":"3849_CR74","doi-asserted-by":"publisher","first-page":"35748","DOI":"10.1038\/srep35748","volume":"6","author":"S Cheng","year":"2016","unstructured":"Cheng S, Aghajanian P, Pourteymoor S, Alarcon C, Mohan S (2016) Prolyl Hydroxylase domain-containing protein 2 (Phd2) regulates Chondrocyte differentiation and secondary ossification in mice. Sci Rep 6:35748","journal-title":"Sci Rep"},{"key":"3849_CR75","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1093\/ndt\/gfs299","volume":"27","author":"J Bacchetta","year":"2012","unstructured":"Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K (2012) The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant 27:3063\u20133071","journal-title":"Nephrol Dial Transplant"},{"key":"3849_CR76","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.2215\/CJN.03630415","volume":"10","author":"S Ploos van Amstel","year":"2015","unstructured":"Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW (2015) Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol 10:2198\u20132204","journal-title":"Clin J Am Soc Nephrol"},{"key":"3849_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1034\/j.1399-3046.2001.00137.x","volume":"5","author":"DW Gjertson","year":"2001","unstructured":"Gjertson DW, Cecka JM (2001) Determinants of long-term survival of pediatric kidney grafts reported to the united network for organ sharing kidney transplant registry. Pediatr Transplant 5:5\u201315","journal-title":"Pediatr Transplant"},{"key":"3849_CR78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/01.TP.0000092524.75807.84","volume":"76","author":"SM Bartosh","year":"2003","unstructured":"Bartosh SM, Leverson G, Robillard D, Sollinger HW (2003) Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation 76:1195\u20131200","journal-title":"Transplantation"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-017-3849-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T05:22:48Z","timestamp":1589865768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-017-3849-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1007\/s00467-017-3849-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"20 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Iain Macdougall has received consultancy fees, speaker fees, and research support from a number of manufacturers of HIF stabilizers, including FibroGen, Astellas, GlaxoSmithKline, Akebia, and Bayer. Dalvir Kular reports no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}